Uptake of Pramipexole ER Will Be Inhibited by Availability of Generic Pramipexole for the Treatment of Parkinson's Disease

When Deciding Whether to Cover an Emerging Parkinson's Disease Drug, Managed Care Organization Pharmacy Directors are Least Influenced by Convenient Formulations, According to a New Report from HealthLeaders-InterStudy and Fingertip Formulary

NASHVILLE, Tenn. and GLEN ROCK, N.J., March 31 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that the uptake of Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading dopamine agonist Mirapex that was approved earlier this month, will be inhibited by competition from generic pramipexole which became available earlier this year. According to the new Formulary Forum report entitled Formulary Advantages in Parkinson's Disease: Which Clinical Endpoints Will Drive Uptake of Emerging Agents?, more than half of surveyed pharmacy directors expect to require patients to fail a generic medication before reimbursing pramipexole ER.

The report also finds the majority of surveyed pharmacy directors will require new treatments to demonstrate improvement in motor symptoms, disease modification or reduction of motor response complications for reimbursement equal to current brands. Surveyed pharmacy directors are least influenced by more convenient formulations.

"Among emerging agents covered in this survey, pramipexole ER was the least likely to be reimbursed by surveyed pharmacy directors—only half expect to reimburse the agent once it launches—supporting our finding that managed care organization pharmacy directors are looking for more than convenience when deciding how to cover emerging Parkinson's disease drugs versus current brands," said Analyst Cindy Fung, Ph.D., author of the report. "The emerging agents surveyed pharmacy directors say they are most likely to cover on commercial and Medicare formularies are all novel therapies, including Solvay's pardoprunox and Acadia/Biovail's pimavanserin."

The new Formulary Forum report is based on a survey of 51 U.S. pharmacy directors who control formularies at national, regional and state-level managed care organizations, as well as historical formulary data from Fingertip Formulary.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com), the leading provider of access to and insight into formulary data in the United States, offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE HealthLeaders-InterStudy; Fingertip Formulary